Europe Western Blotting Market Forecast Analysis 2024-2032

Europe Western Blotting Market Forecast Analysis 2024-2032

According to Triton’s analysis, the Europe western blotting market is projected to rise at a CAGR of 4.06% in revenue over the forecast years 2024-2032.

The demand for the western blotting market in the European region is expected to grow due to the widespread awareness programs in many low- and middle-income countries that educate people on the fundamentals of HIV. These initiatives, along with funding from global organizations for free testing and treatment options, will create significant opportunities for manufacturers of western blotting products. Additionally, multilateral organizations, including UNITAID, the Global Fund, and other United Nations agencies, have been actively providing financial support for HIV-related efforts across the region.

The countries explored in this region include the United Kingdom, Germany, France, Spain, Italy, and Rest of Europe.

The United Kingdom secures a major market share with revenue of approximately $48.23 million in 2023.

• As per the UK parliament, approximately 107,000 people in the UK are estimated to be living with HIV, which increases the demand for confirmatory testing using western blotting, which is essential after initial HIV screenings.
• Ongoing monitoring of HIV patients requires western blotting to detect viral proteins and antibodies, boosting the use of western blotting consumables.
• Research into HIV treatments and diagnostics in the UK further drives the demand for western blotting in laboratories and research centers.
• Government funding and support for HIV research and personalized medicine initiatives also promote the growth of the western blotting market.

Western Blotting Market Forecast for Germany

Germany, classified as a Pattern I country by the WHO, witnesses most new HIV infections among high-risk populations. However, trends are shifting, with an increasing proportion of women—now accounting for 20% of new infections—being reported as newly infected. Additionally, the country’s policy of granting immediate access to new treatments following global approvals has created a healthcare system rich in treatment options but lacking in comprehensive professional guidance on treatment strategies and safety. As new cases rise and the diversity of patients expands, there is a need for ongoing monitoring and evaluation of the efficacy of new treatment strategies, resulting in the increased demand for western blotting methods.

The western blotting market is segmented based on product, end-user, and application. The product segment comprises consumables and instruments. The consumables include essential products required for the process, such as reagents, buffers, etc. Reagents and buffers are used for sample preparation, protein transfer, and detection, while primary and secondary antibodies play a key role in identifying target proteins.

Contender Analysis in the Western Blotting Market:

Bio-Techne Corporation, formerly known as TECHNE Corporation develops, manufactures, and sells biotechnology products and clinical diagnostic controls. The company offers specialized proteins such as cytokines and growth factors, along with immunoassays, small molecules, and other reagents for the research, diagnostics, and clinical control markets. The company operates across the US, Europe, and Asia, with its headquarters in Minneapolis, Minnesota.

In July 2024, Bio-Techne introduced a next-generation Simple Western system that surpasses the current Jess and Abby models in throughput, flexibility, and efficiency. This advanced instrument can process up to 100 samples simultaneously in just 3 hours, significantly increasing the number of samples scientists can analyze in a single day.

Other contenders in the studied market are Lumigen Inc, Rockland Immunochemicals Inc, Enzo Biochem Inc, Geno Technology Inc, Stressmarq Biosciences Inc, etc.